Dr. Andrew Rezvani, MD
Claim this profileStanford University
Studies Non-Hodgkin's Lymphoma
Studies Leukemia
7 reported clinical trials
12 drugs studied
Area of expertise
1Non-Hodgkin's Lymphoma
Philadelphia Chromosome positive
CD22 positive
CD22 negative
2Leukemia
CD19 positive
CD22 negative
CD19 negative
Affiliated Hospitals
Clinical Trials Andrew Rezvani, MD is currently running
Axicabtagene Ciloleucel
for Non-Hodgkin Lymphoma
This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.
Recruiting1 award Phase 1
Unlicensed Cord Blood Transplant
for Blood/Immune System Disorders
This trial is testing the safety of giving patients special blood from umbilical cords. The study focuses on patients who receive these infusions to see if there are any serious side effects. The cord blood has special cells that can help make new blood cells in the body. Umbilical cord blood has been used in the treatment of various diseases for many years, including leukemia, lymphoma, and congenital immunodeficiency.
Recruiting1 award Phase 21 criteria
More about Andrew Rezvani, MD
Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Andrew Rezvani, MD has experience with
- Cyclophosphamide
- CD22 CAR
- Fludarabine
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells
- Fludarabine Phosphate
- NKTR-255
Breakdown of trials Andrew Rezvani, MD has run
Non-Hodgkin's Lymphoma
Mixed-Cell Lymphoma
Mediastinal Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Rezvani, MD specialize in?
Andrew Rezvani, MD focuses on Non-Hodgkin's Lymphoma and Leukemia. In particular, much of their work with Non-Hodgkin's Lymphoma has involved Philadelphia Chromosome positive patients, or patients who are CD22 positive.
Is Andrew Rezvani, MD currently recruiting for clinical trials?
Yes, Andrew Rezvani, MD is currently recruiting for 4 clinical trials in Palo Alto California. If you're interested in participating, you should apply.
Are there any treatments that Andrew Rezvani, MD has studied deeply?
Yes, Andrew Rezvani, MD has studied treatments such as Cyclophosphamide, CD22 CAR, Fludarabine.
What is the best way to schedule an appointment with Andrew Rezvani, MD?
Apply for one of the trials that Andrew Rezvani, MD is conducting.
What is the office address of Andrew Rezvani, MD?
The office of Andrew Rezvani, MD is located at: Stanford University, Palo Alto, California 94305 United States. This is the address for their practice at the Stanford University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.